Rider, J. Alfred
June 1960
American Journal of Gastroenterology;Jun1960, Vol. 33 Issue 6, p734
Academic Journal
Stools collected for a 72-hour period during Doxegest therapy were compared to control collections. There appears to be no objective evidence that Doxegest causes any change in the excretion of fat or nitrogen. Clinically, however, of 10 females treated for periods of 3 weeks to 6 months, 2 had excellent results, 6 had good effect, and 2 had no effect. The age of the patient appeared to be insignificant in the clinical results. Of 12 males who were treated for periods of 3 weeks to 12 months, 3 had excellent results, 3 had good results, and 2 had fair results. Four patients experienced no effect. The placebos which were given to 10 patients who had reported some benefit from Doxegest therapy gave "no effect" in 8, fair results in one, and good results in one.


Related Articles

  • Chelsea completes enrollment for Phase II hypotension trial.  // PharmaWatch: Biotechnology;Jan2009, Vol. 8 Issue 1, p5 

    The article reports on the patient enrollment completed by Chelsea Therapeutics International Ltd. in its Phase II trial of Droxidopa in patients with intradialytic hypotension in the U.S. The trial is a multi-center, double-blind, placebo controlled study that compared 400 milligrams (mg) and...

  • Rebuttal to Dr Streiner: Can the "Evil" in the "Lesser of 2 Evils" Be Justified in Placebo-Controlled Trials? Glass, Kathleen Cranley // Canadian Journal of Psychiatry;Jul2008, Vol. 53 Issue 7, p433 

    The author reflects on the research findings of David Streiner that justify the ethical applications of placebo-controlled trials in Ontario. She argues the worst cases recognized by Steiner as he concluded that the trials offered the most effective treatment at lower risk. She compares...

  • Enhanced IL-4 Production and IL-4 Receptor Expression in Atopic Dermatitis and Their Modulation by Interferon-Gamma. Renz, Harald; Jujo, Kazuhito; Bradley, Katherine L.; Domenico, Joanne; Gelfand, Erwin W.; Leung, Donald Y. M. // Journal of Investigative Dermatology;Oct92, Vol. 99 Issue 4, p403 

    The in vivo and in vitro immunomodulatory effects of interferon gamma (IFN-γ) treatment on peripheral blood mononuclear cells (PBMC) from patients with atopic dermatitis (AD) and elevated IgE levels were studied. As part of a double blind placebo-controlled clinical trial, 14 AD patients were...

  • Meta-Analysis: Effect of Long-Acting β-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths. Salpeter, Shelley R.; Buckley, Nicholas S.; Ormiston, Thomas M.; Salpeter, Edwin E. // Annals of Internal Medicine;6/20/2006, Vol. 144 Issue 12, p904 

    Background: Long-acting β-agonists may increase the risk for fatal and nonfatal asthma exacerbations. Purpose: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting β-agonists. Data Sources: English- and non-English-language searches of...

  • Is there a place for placebo controlled trials of antiepileptic drugs? Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford // British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328 

    Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.

  • Withholding Proven Treatment in Clinical Research. Huston, Patricia; Peterson, Robert // New England Journal of Medicine;9/20/2001, Vol. 345 Issue 12, p912 

    Editorial. Discusses the ethics of placebo-controlled clinical trials. Role of the Declaration of Helsinki; Need for scientific and ethical justification of the use of placebos.

  • Is the Placebo Powerless? Hróbjartsson, Asbjørn; Gøtzsche, Peter C. // New England Journal of Medicine;05/24/2001, Vol. 344 Issue 21, p1594 

    Background: Placebo treatments have been reported to help patients with many diseases, but the quality of the evidence supporting this finding has not been rigorously evaluated. Methods: We conducted a systematic review of clinical trials in which patients were randomly assigned to either...

  • An Evaluation of Arbaprostil at Multiple Doses for the Treatment of Acute Duodenal Ulcer: A Randomized Double Blind Placebo-Controlled International Trial. Euler, A. R.; Krawiec, J.; Odes, H.; Gilat, T.; Garcia, L.; Rachmilewitz, D.; Gabryelewicz, A.; Gibinski, K.; Bass, D.; Barbara, L.; Porro, G. Bianchi; Lazzaroni, M.; Kirchmayer, S.; Nago-Nago, A.; Popiela, T.; Kulig, J.; Roca, M.; Hagenmuller, F.; Bergemann, W.; Schryver, M. // American Journal of Gastroenterology;Feb1990, Vol. 85 Issue 2, p145 

    Six hundred and thirty patients were enrolled in a randomized double-blind placebo-controlled trial evaluating two arbaprostil dosages (25 µg and 50 µg) qid for 4 wk for the treatment of acute duodonal ulcers. The healing rates in the placebo, 25-µg, and 50-µg treatment groups were...

  • Importance of Placebo Effect in Cough Clinical Trials. Eccles, Ron // Lung;Feb2010 Supplement 1, Vol. 188, p53 

    Cough is a unique symptom because, unlike sneeze and other symptoms, it can be under voluntary control and this complicates clinical trials on cough medicines. All over-the-counter cough medicines (OTC) are very effective treatments because of their placebo effect. The placebo effect is enhanced...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics